Diabetes
Conditions
Brief summary
The Hanapū Study: Incentivized Partnerships to Reduce Diabetes Disparities is a randomized control trial that will test the effectiveness of partnership incentives plus evidence-based education to optimize glycemic outcomes among diabetic patients compared with usual care.
Detailed description
The Hanapū Study will use a block randomization study design to enroll 100 diabetic patients in each arm (n = 200) followed over 9 months. Providers will identify diabetic patients. After the baseline visit is completed, patient(s) and their provider will be randomized to either Intervention or Usual care arm as partners. The intervention arm will receive diabetes self-management education and modest financial incentives (gift cards) for completing diabetes process and glycemic outcomes according diabetes best practices. Usual care patients will receive an equal number of educational materials on diabetes self-management via mail and will receive usual care through their provider but will not receive additional incentives for reaching glycemic outcomes. Both arms of the study will complete outcome visits at baseline, 4.5 and 9 months.
Interventions
OTHERMa ka hana ka ̒ike
Ma ka hana ka ̒ike is a self-management program for diabetic patients which includes 5 interactive group sessions lasting 1-1/2 hours in length delivered by community peer educators once a month for 6 months.
OTHERHanapū Provider Toolbox
Hanapū Provider Toolbox is an educational tools that will aid the health care providers in guiding their patients to optimal glycemic control.
Sponsors
National Institute on Minority Health and Health Disparities (NIMHD)
University of Hawaii
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Confirmed diagnosis of diabetes mellitus * HbA1c \>7% * Not planning to move out of the State * Able to fully participate in either intervention or usual care arms.
Exclusion criteria
* Pregnancy * End Stage Renal Disease requiring dialysis * Any medical condition that would prevent participation in all aspects of the study protocol (including major psychiatric diagnosis) or with \< 6 month expected survival, as determined by the patient's physician.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change of HbA1c | Baseline, 4.5 months and 9 months | HbA1c assessment will be done at baseline and during the intervention follow up periods (4.5 and 9 months) to see incremental improvement (0.5% decrease in HbA1c) or achieving optimal control (HbA1c \< 7%). |
Outcome results
None listed